Leukemia Clinical Trials

Showing 2901-2920 of 10,987 trials

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

NCT03787992

To assess the efficacy and safety of Alflutinib Mesylate versus Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

Allist Pharmaceuticals, Inc.358 participantsStarted May 2019

Beijing, China

RECRUITING

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

NCT06833229

The hypothesis of this prospective observational pilot study of diagnostic diagnostic performance is that, for patients with NSCLC treated with immunotherapy associated or not with chemotherapy, certain metabolic biomarkers on 18FDG PET scans allow early identification of treatment response (or lack of response to treatment) and optimize prediction of tumor response compared with current standards.

Carcinoma, Non-Small-Cell Lung (NSCLC)

Centre Antoine Lacassagne200 participantsStarted Jan 2022

Nice, France

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

Related Searches

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells

AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry

Breath Analysis for the Detection of Invasive Fungal Infections

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

Transcranial Temporal Interference Stimulation In Severely Brain Injured Patients With Disorders of Consciousness

VIRal Hepatitis and GAllstone Disease Study

Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia

Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)